1. Cell-free DNA testing for early hepatocellular carcinoma surveillanceResearch in context
- Author
-
Lei Chen, Tong Wu, Rong Fan, Yun-Song Qian, Jing-Feng Liu, Jian Bai, Bo Zheng, Xiao-Long Liu, Dan Zheng, Lu-Tao Du, Guo-Qing Jiang, Ying-Chao Wang, Xiao-Tang Fan, Guo-Hong Deng, Chun-Ying Wang, Feng Shen, He-Ping Hu, Qing-Zheng Zhang, Yi-Nong Ye, Jing Zhang, Yan-Hang Gao, Jie Xia, Hua-Dong Yan, Min-Feng Liang, Yan-Long Yu, Fu-Ming Sun, Yu-Jing Gao, Jian Sun, Chun-Xiu Zhong, Yin Wang, Hui Wang, Fei Kong, Jin-Ming Chen, Hao Wen, Bo-Ming Wu, Chuan-Xin Wang, Lin Wu, Jin-Lin Hou, and Hong-Yang Wang
- Subjects
Early hepatocellular carcinoma ,Surveillance ,Cell-free DNA ,Liquid biopsy ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Liver cirrhosis (LC) is the highest risk factor for hepatocellular carcinoma (HCC) development worldwide. The efficacy of the guideline-recommended surveillance methods for patients with LC remains unpromising. Methods: A total of 4367 LCs not previously known to have HCC and 510 HCCs from 16 hospitals across 11 provinces of China were recruited in this multi-center, large-scale, cross-sectional study. Participants were divided into Stage Ⅰ cohort (510 HCCs and 2074 LCs) and Stage Ⅱ cohort (2293 LCs) according to their enrollment time and underwent Tri-phasic CT/enhanced MRI, US, AFP, and cell-free DNA (cfDNA). A screening model called PreCar Score was established based on five features of cfDNA using Stage Ⅰ cohort. Surveillance performance of PreCar Score alone or in combination with US/AFP was evaluated in Stage Ⅱ cohort. Findings: PreCar Score showed a significantly higher sensitivity for the detection of early/very early HCC (Barcelona stage A/0) in contrast to US (sensitivity of 51.32% [95% CI: 39.66%–62.84%] at 95.53% [95% CI: 94.62%–96.38%] specificity for PreCar Score; sensitivity of 23.68% [95% CI: 14.99%–35.07%] at 99.37% [95% CI: 98.91%–99.64%] specificity for US) (P
- Published
- 2024
- Full Text
- View/download PDF